guidanc beatabl focu
execut pt rais
believ guidanc conserv also believ
beatabl updat model assum treatment
us neurolog patient treat soliris/ultomiri vs guidanc
neurolog spoke manag extens price
beat guidanc would give us confid reach ambit treat
us neurolog patient could add addit
dcf view rais pt
reiter buy
guidanc beatabl view updat model rang
compani top-line guidanc
believ guidanc conserv beatabl beat guidanc
would give confid reach ambit treat us neurolog
patient could add addit dcf
view guidanc impli top-line yoy growth compar
like disappoint investor believ beatabl focu
investor execut throughout year us germani
japan territori make total revenu base believ room
growth territori help expect launch
ultomiri high concentr de-risk view given
larg manufactur upgrad conveni reduc infus time
min ultomiri launch eu territori pnh
expect strong convers launch seen us germani
japan indic fast launch addit expect
convert us pnh patient leav half
year test larg portion convert test whether
convers may conserv see mani opportun beat
spoke manag extens price believ
price becom key factor reach patient base
speak manag believ treat high volum patient
strateg price import believ treat patient
could warrant price reduct everi addit patient possibl
reduc price addit pnh current
premium ultomiri price soliri year treatment due load
dose follow discount pnh mainten discount
tr target
ahu patient year follow discount next year recal manag
consist said expect maintain price flexibl align volum opportun
valu ultomiri offer view believ import data point deck
expect ultomiri expand mg patient popul vs prior could also see
addit patient thrombot microangiopathi tma
model us neurolog patient treat soliris/ultomiri vs guidanc
neurolog updat model increas neurolog patient treat
soliri ultomiri us expect us neurolog patient treat
consequ rais peak sale mg/nmo
pt increas treat neurolog patient
could see addit dcf expand address mg patient
note elig mg patient could larg base ultomiri treatment
also note model conserv street may overestim
impact competit model share loss competit biosimilar price
pressur howev think fair keep share moment see stock trade
pt overhang remov one one especi august ipr decis compani highlight
neurolog largest franchis patient volum within year launch pleas see
initi detail analysi pleas ask model competit app
input assumpt
key catalyst whether beat consensu catalyst includ updat
ultomiri convers pnh ahu year ultomiri subq data readout
danicopan initi pnh wilson diseas complet
enrol soliri ipr decis august data pnh nave
trial competitor gmg data imvt data data argx pivot
data
august ipr decis key overhang stock remind file ipr
challeng soliri patent believ market strh model
assum win entri biosimilar soliri earn call manag
highlight issuanc addit method use patent soliri pnh ahu us
could potenti provid addit ip protect need work first
know may impact stock remind alexion alreadi patent us
protect soliri pnh late believ key overhang stock stock
typic well ipr outcom challeng howev recommend
own stock ipr believ stock could recov decis irp
releas even lose remov uncertainti
model updat quarter estim updat updat model reflect
actual quarter updat estim within rang guidanc
higher end soliris/ultomiri guidanc vs guidanc
page
figur million dollar except per share data
strh research compani report updat
page
incom statement market productsproduct revenu sale pediatr unadjustedultomiri non-refractori al product oper oper itemsinvest interest incom currenc gain expens incom exc spec tax incom non-gaap cash tax excl stock ep ex-opt tax net incom non-gaap ep incl share share share dilut use non-gaap inc
alexion pharmaceut inc biopharmaceut compani focus serv patient
devast ultra-rar disord develop commerci life-
transform therapeut product compani product includ ultomiri soliri strensiq
kanuma compani found joseph madri david keiser stephen squinto
leonard bell januari headquart boston
buy-rat share next month think
investor clariti us pnh patent see risk reward buy
karnauska ipr favor current level recommend own alexion
ipr outcom august believ investor expect win alexion
lose soliri pnh patent win see upsid uncertainti remov
lose could even upsid pt
view current valu stock reflect invalid alexion us pnh patent
price pressur soliri keep market share approv indic
credit pipelin believ unrealist given convers ultomiri go ahead
expect model give signific share biosimilar us eu
also believ compani could beat consensu estim see qualiti
compani execut repeatedli beat expect mg growth ultomiri
see data apelli nr pnh ra rarx hold mg apelli
studi head head soliri believ soliri patient extravascular
hemolysi smaller investor believ rout administr
challeng mani patient ultomiri dose everi two month also believ current
level assum competit model
acknowledg stock may achiev upsid tp ahead ipr
uncertainti consensu estim beyond appear erod alexion
busi much may need come
valuat risk
pt deriv use dcf use discount factor believ appropri
larg cap biotech lower risk profil competit risk versu peer assum
termin valu reflect alexion creat valu cash gener assum alexion lose ipr
august soliris/ultomiri make follow assumpt pnh share ultomiri
competit biosimilar ahu share ultomiri competit
biosimilar mg ultomiri competit biosimilar peak
treat us neurolog patient despit popul nmo ultomiri
competit biosimilar price model price cut soliri ultomiri
competit give zero valu pipelin
risk rate price target includ price share erod greater faster expect
greater competit clinic trial failur pipelin
compani mention note
robyn karnauska herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
page
